Yazen raises 50 million euros to pair Ozempic with coaching, despite a regulator's doubts.

A European weight-loss clinic just raised its biggest round yet

Yazen Health, a Swedish digital healthcare company, raised 50 million euros this month in a round led by growth investor Verdane, which becomes its largest shareholder. Evli Growth Partners, the firm that led Yazen's 19.5 million euro Series A back in 2024, came back for this one too. It's the company's biggest raise since it launched in 2021, more than double the Series A, and it lands at a moment when GLP-1 drugs like Ozempic have gone from prescription-only diabetes medication to a mainstream weight-loss category with its own telehealth industry forming around it.

What Yazen actually sells

Yazen isn't a pharmacy. It's a subscription service that wraps a GLP-1 prescription in ongoing care: doctors who assess and prescribe, plus dietitians, psychologists and physiotherapists who coach patients through the process. Reporting on its business model puts the coaching and consultation subscription at roughly 90 euros a month, separate from the cost of filling the actual prescription at a partner pharmacy. The company says it has treated more than 70,000 patients in total and currently has over 50,000 active across eight European countries, including its home market of Sweden and newer markets such as the Netherlands.

That's the pitch: obesity is a chronic condition, not a matter of willpower, and a drug alone doesn't fix the habits, side effects and plateau periods that come with it. CEO Fredrik Meurling put it plainly in the funding announcement: Obesity is, in his words, "a chronic, progressive disease, not a character flaw."

The money behind the round

Verdane's principal Cecilia Nytorp said the firm was impressed by the Yazen team and the momentum it is demonstrating, and pointed to the company's clinical data as a factor in the investment. That data point matters more than it might sound: Yazen's finances show a company growing but still unprofitable. Revenue reached about 29.4 million euros in its 2025 financial year, up sharply from earlier years, but the company posted an EBITDA loss of roughly 5.7 million euros over the same period. The new capital is earmarked for expanding the care model into more European markets rather than for turning a profit anytime soon.

The regulatory scrutiny that came before this raise

What the funding announcements don't mention is that Yazen was, less than two years before this round, the subject of a formal safety complaint. In February 2025, Sweden's health and social care inspectorate, IVO, criticized the company over how it verified patients before prescribing Ozempic. According to IVO's findings, patients could submit their own photos and self-reported measurements, which left the system open to manipulation. An inspector told reporters that patients could send pictures of other, more overweight people and state the wrong values and measurements, calling it a serious problem. A separate source described doctors facing pressure to prescribe quickly, even when test results or signs of other health issues raised doubts.

Yazen's response at the time, from chief medical officer Martin Carlsson, was that the criticism was partly outdated and that the company had already made changes to its process, having by then treated roughly 25,000 patients. Nothing in the public record since suggests the case produced a fine or formal penalty, but it's a useful reminder that a polished funding announcement and a regulator's findings can describe the same company in very different terms within the same two years.

Does the coaching layer actually hold up

The honest answer is that it depends entirely on execution, and execution is exactly what got flagged. The clinical argument for pairing GLP-1 drugs with structured coaching is reasonable. Studies on semaglutide and tirzepatide consistently show better weight maintenance when medication is combined with behavioral support, and a dietitian or psychologist can catch problems a pharmacy fulfillment service never will. But that argument only holds if the people doing the assessing are actually assessing, not rubber-stamping self-reported numbers to keep subscription volume up. Yazen is competing against both pharma-run direct-to-consumer programs from Novo Nordisk and Eli Lilly, and scaled US telehealth platforms, all chasing the same patients. The pressure to grow fast and the pressure to prescribe carefully tend to pull in opposite directions, which is the tension Yazen's own regulator pointed at. For context on how that tension plays out elsewhere in the GLP-1 supply chain, see how pharmacy benefit managers are also racing to capture GLP-1 margins.

Our take

Fifty million euros is a real vote of confidence in the idea that GLP-1 weight loss works better with support attached, and the demand numbers back that up. But investors are betting on a clinical promise that a national regulator has already questioned once. If you're weighing a subscription clinic like Yazen against simply getting Ozempic or Wegovy from your own doctor, the coaching is only worth the extra cost if the assessment behind it is rigorous, not rushed.

Health Trend Wire holds no position in Yazen and was not paid for this article. This is general information, not medical or financial advice.